



Lilly Cares Foundation
2018 Annual Report



"Lilly Cares was there to help me in my time of need... I don't know what I would've done without this help. Everyone I have worked with has been so thoughtful and caring! You have no idea how much this means to me, again thank you very much!"



For the past 20 years, the Lilly Cares Foundation Inc. (Lilly Cares) has existed for a single purpose: to enable those in the United States who have a significant financial need to receive prescribed Eli Lilly and Company (Lilly) medications at no cost. Fortunately, most Americans have sufficient insurance or government assistance to access the life-saving and life-enhancing medications they need. However, for some, income and insurance coverage limitations put certain medical treatment out of reach.


The Lilly Cares Patient Assistance Program (PAP) was created to help solve medicine access challenges for those who are financially vulnerable, allowing these patients to manage their illness in the toughest times.

This is our first year to create an annual report for our nonprofit organization. With more than a million people Lilly Cares has impacted over the years, we felt it was important to provide a summary of our annual efforts. 2018 was a particularly active year for Lilly Cares, with more than a billion dollars¹ in medication provided to patients, and many changes to eligibility requirements, medication offerings, and operations. These changes reflect our focus on our charitable mission and on continual improvement to best support patients and their caregivers.

I hope you find this report enlightening, and you will share information about Lilly Cares and other PAPs with those who may benefit from these services. Please visit www.lillycares.com for more information about the Lilly Cares PAP.

Steve Stapleton
President, Lilly Cares Foundation, Inc.

¹ Based on Average Wholesale Price.



"I do not have the words to express my gratitude for what you have done with Forteo... I had no way to cover the cost of Forteo, but you have enabled me to set out on this journey. My prayer is... that so many others you help will know that same blessing."

2018 ACHIEVEMENTS

The Patients We Served



121,000+ total patients served

Lilly Cares served over 121,000 patients in 2018, 9% more than in 2017. Patients enrolled in the Lilly Cares PAP receive medications at no cost for up to 12 months per enrollment period.



52,000+ patients provided diabetes medicines

Diabetes has continued to grow in the U.S., with the number of people with diabetes having tripled in the past 20 years.² Diabetes can be a particular challenge for those with limited income considering the number of required medical treatments, supplies, and doctor visits, as well as additional health issues patients with diabetes often face. Lilly Cares is proud of its ability to provide life-saving medications for so many with significant financial need living with diabetes.



47,000+ patients provided mental health medicines

Nearly 1 in 5 adults live with mental illness³, and Lilly Cares understands the critical role medications can play in the treatment of disorders such as depression, anxiety and schizophrenia, enabling patients to live happy, productive lives. For the many facing both the daily challenges of mental illness and the challenges that come with personal financial struggles, Lilly Cares is committed to do its part to help these individuals obtain the medications they need to enjoy positive mental health.



2,000+ patients provided cancer medicines

At Lilly Cares, we feel it's a special privilege to be a part of the care and support for a patient facing cancer. For eligible patients, we provide infused and oral oncology medications that treat some of the most common cancers in the U.S., such as breast, lung, and colorectal cancers at no cost.




14,000+ patients provided women and men's health medicines.



5,000 patients provided specialty care medicines

Lilly Cares assisted more than 19,000 patients in 2018 with accessing medications for life threatening and debilitating disorders such as cardiovascular disease, osteoporosis, rheumatoid arthritis, migraine, erectile dysfunction, psoriasis, and growth hormone deficiency.

The Value of Lilly Cares Medicines



» Lilly Cares provided more than **\$1.12 billion**⁴ in medicines in 2018.

2 <https://www.cdc.gov/chronicdisease/resources/publications/aag/diabetes.htm>

3 www.nimh.nih.gov/health/statistics/mental-illness.shtml

4 Based on Average Wholesale Price.

LILLY CARES PAP CHANGES IN 2018

New Medication Offerings

In 2018, Lilly Cares began providing OLUMIANT® (baricitinib) tablets to eligible adults with active rheumatoid arthritis and Emgality® (galcanezumab-gnlm) injection to eligible adults seeking a preventive treatment for migraines.

Changes to Financial Eligibility

Lilly Cares revised its financial eligibility criteria for individuals living with diabetes who have been prescribed Lilly diabetes medications. Applicants with an adjusted gross household income of less than or equal to 400 percent of the federal poverty level (FPL) may now qualify for Lilly Cares, provided they meet all other program eligibility criteria.

Lilly Cares also revised its financial eligibility criteria for patients prescribed Taltz® (ixekizumab) injections. People with an adjusted gross household income of less than or equal to 500 percent of the FPL may now qualify for Lilly Cares, provided they meet all other program eligibility criteria.

Expanding in Puerto Rico

We expanded our full offering of medications to assist those patients in need who live in Puerto Rico.

On-line Applications

Patient and health care providers now have the option of completing their Lilly Cares PAP applications online in addition to using a paper-based application. The new platform is designed to make the application process simpler and quicker.

Other Eligibility Changes

Lilly Cares made a number of adjustments to our insurance coverage requirement in 2018.

Lilly Cares applicants with Medicare Part B coverage but without supplemental or secondary insurance are now eligible for Lilly Cares oncology medications, provided they meet all other program eligibility requirements. We also implemented changes in an effort to speed up the application review process and reduce the burden on patients applying for Lilly Cares.

These changes include no longer requiring patients enrolled in Medicare to provide a copy of their Part D card, and removing the requirement that patients potentially eligible for Medicaid or a full Medicaid Low Income Subsidy (LIS) apply for, and be denied access to these programs before being considered for the Lilly Cares PAP. However, those who are enrolled in Medicaid or a full LIS continue to be ineligible for Lilly Cares.

88%

Percent of people who applied and were approved for enrollment.

78%

Percent of applications processed within 3 days.

98%

Percent of applications processed within 5 days.



“Thanks so much for everything you all have done for our mother. Your organization has literally saved our mother through all of its help and dedication.”

LILLY CARES MEDICATIONS PROVIDED IN 2018

Diabetes

Basaglar® (insulin glargine injection)
Humalog® (insulin lispro injection)
Humulin® (human insulin [rDNA origin])
Glucagon (glucagon for injection [rDNA origin])
Trulicity® (dulaglutide)

Mental Health

Cymbalta® (duloxetine delayed-release capsules)
Prozac® (fluoxetine)
Strattera® (atomoxetine)
Symbyax® (olanzapine and fluoxetine)
Zyprexa® (olanzapine)

Cancer

Alimta® (pemetrexed for injection)
Cyramza® (ramucirumab)
Erbix® (cetuximab)
Gemzar® (gemcitabine)
Lartruvo® (olaratumab)
Portrazza® (necitumumab)
Verzenio® (abemaciclib)

Women's and Men's Health

Cialis® (tadalafil)
Evista® (raloxifene hydrochloride)
Forteo® (teriparatide [rDNA origin] injection)

Specialty Care

Effient® (prasugrel)
Emgality® (galcanezumab-gnlm) injection
Humatrope® (somatropin) for injection
Olumiant® (baricitinib) tablets
Taltz® (ixekizumab) injection

Top 10 Lilly Medications Provided in 2018

Humalog: 23,320 patients
Cymbalta: 22,300 patients
Trulicity: 14,609 patients
Prozac: 11,836 patients
Forteo: 9,021 patients
Zyprexa: 8,916 patients
Humulin: 8,160 patients
Basaglar: 6,044 patients
Cialis: 4,991 patients
Strattera: 4,001 patients

State-level numbers regarding patients served through Lilly Cares in 2018 can be found on lillycares.com/news.



"I am a nurse with a small health clinic in Kansas. I am writing to thank you most sincerely for all the help [Lilly Cares] has given our patients throughout the year. Your assistance often made the difference between the patient having the medication or not. I hope that this season brings you all the blessings you have provided for others."



Lilly Cares Foundation, Inc., Lilly Corporate Center
Indianapolis, IN 46285

All medications listed in this report are registered trademarks owned or
licensed by Eli Lilly and Company, its subsidiaries or affiliates.

PP-AP-US-0359 04/2019 ©Lilly USA, LLC 2019.
All rights reserved.